Stay updated on High Dose Cytarabine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page
- Check2 days agoChange DetectedDifference0.3%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page revision was updated from v3.2.0 to v3.3.2, with no substantive changes to the study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check32 days agoChange DetectedRemoved the government funding lapse disclaimer from the page. This does not alter the study details or how a user would interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check46 days agoChange DetectedUpdated Study Record Dates show the last update posted on 2024-09-25 and a revised record status. The core study design details appear unchanged.SummaryDifference0.4%

- Check75 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference2%

- Check82 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0. No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to High Dose Cytarabine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.